mani challeng downgrad
downgrad hold buy manag
team strong track record navig headwind valuat
sit discount peer see secular growth challeng number
front studi issu reduc condenc challeng
resolv favor thu see downsid street organ revenu
growth expect absent upsid number see limit
opportun stock out-performance especi follow stock run
past month would construct convict
organ sale growth achiev sustain
structur growth challeng across board
face structur growth challeng mani busi
breast imag pap medic aesthet well known studi
suggest investor mind deceler diagnost
sale challeng gyn surgic
ckle natur cyclic medic aesthet adjust
acquisit time actual comfort outlook
breast imag busi follow strong result past
month reduc organ revenu growth forecast
previous compar street forecast
headwind horizon diagnost
see sever reason growth compani diagnost segment
deceler recent level promin among pressur
pap busi expand test interv and/or new guidelin
elimin recommend co-test doc call suggest
guidelin near-term eect pap human papillomaviru hpv
test volum nonetheless believ continu stabil
base case model molecular diagnost star perform
portfolio growth like deceler number reason less
lab custom
unclear gyn surgic
reduc sale forecast gyn surgic busi follow
lower-than-expect perform busi miss street
revenu forecast everi quarter quarter row sinc benet
competit withdraw annual unclear see heighten
price jan usd
buy hold
price target risk pt
reect enterpris valu use project
level debt cash
ttm ebitda ex option
multipl discount medic
devic peer group multipl
med devic compani grow sale
organ upsid risk price
target includ faster revenu growth
ep leverag downsid risk
price target includ slowdown capit
expenditur longer plan path
recoveri medic aesthet
advers chang reimburs and/or
guidelin product
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
competit novasur less increment market opportun avail
myosur expect recent manag chang surgic
harder get excit upsid aesthet
continu believ medic aesthet busi return
double-digit growth base easi comparison sale forc revamp favor
underli demand trend medic aesthet new product launch
said less excit growth opportun previous
magnitud chang cynosur growth rate immedi post acquisit
sale fell month end compar growth
prior month point swing someth seen
speak ckle natur aesthet market previous
appreci increment doc call cast doubt ecaci
bodi sculpt dispar feedback categori common class
action lawsuit challeng perform sculpsur help view
moreov aesthet econom sensit busi
revenu equipment-heavi procedur discretionari
whi econom downturn next year forecast double-digit
benet tax reform alreadi stock
stock bare budg vs jan
announc tax rate would fall rang well
prior guidanc interpret tax reform upsid alreadi fulli
stock increas ep forecast accordingli could see
upsid compani reinvest less benet assum note
assum medic devic tax return compani
washington dilig suggest reason assumpt tax
repeal would pare back ep increas optic
street ep street updat new tax guidanc lag
valuat optic attract depend comp group enough carri
stori
stock trade discount devic peer one featur
turn stori consensu long sell-sid buy hold
sell howev compar devic peer grow sale less
organ stock trade line forward ebitda
discount forward price-to-earnings discount probabl narrow
street estim peer updat tax reform struggl see multipl
expans could see slight contract compani miss street organ
forecast ratio
diagnost headwind horizon
chang cervic cancer screen recommend could pose
molecular golden child growth like deceler
medicar price pressur time unfortun larg contract
competit environ novasur
myosur strength less increment opportun therapeut
horizon
chang cervic cancer screen recommend
final draft guidelin like event think current form
recal unit state prevent servic task forc uspstf issu
draft updat cervic cancer screen guidelin sept exclud
hpv pap co-test women chang departur prior
guidelin recommend co-test follow tabl illustr
chang guidelin time
figur summari recent chang uspstf cervic cancer screen
final draft guidelin current form could pose headwind
diagnost busi market leader hpv
pap test estim compris nearli sale much
 -base
use time lag draft naliz guidanc colorect cancer
screen preced month believ naliz cervic cancer
screen guidanc could occur highlight
opposit uspstf draft cervic cancer screen guidanc current
form understand rare task forc chang perspect
draft nal
inde data summari analys behind uspstf recommend
appear us well consid includ random control trial
cohort studi pap vs cotest studi found co-test better
sensit signicantli fals posit higher led
uspstfseptemb draftwomencerv cytolog alonehrhpv alonecerv cytolog hrhpv comboag yearseveri year aloneno mentionno yearseveri year aloneeveri year alonenoold cytolog alonehrhpv alonecerv cytolog hrhpv comboag yearseveri year yearseveri year aloneno mentioneveri yearsold march cytolog alonehrhpv alonecerv cytolog hrhpv comboag yearsconvent pap annual liquid-pap everi yearsannu unless three normal pap test row everi yearsold year start vagin intercours januari
 follow-on test colposcopi studi aw
quest diagnost sponsor studi cervic cancer
screen result among women sourc claim primari hpv
test miss nearli cervic cancer plenti aw
studi consid patient cervic biopsi within year co-test
thu sampl massiv enrich incid cervic lesion
believ sampl bia overst sensit pap specic
method studi fals posit primari challeng screen
method believ potenti fals posit under-st
studi given sampl bia still posit predict valu test
studi method studi critic hpv
primari screen includ result hpv test
 approv primari screen
see immedi chang test order predic point toward eventu
downsid mute somewhat
discuss ob/gyn suggest even uspstf draft guidelin
naliz current form guidelin would unlik inuenc
clinic practic near term reason view includ concern
miss cervic cancer well guidelin updat fatigu
payer could hasten complianc histor seen payer reluct
reduc screen servic women health irrespect guidelin
exampl even though uspstf medic societi american cancer
societi american colleg obstetrician gynecologist acog
recommend co-test cervic cancer year interv sinc
aetna aet reimburs co-test year interv
commerci plan
predic exampl guidanc chang suggest impact get
better sens scale rate impact look two histor case
believ provid close analogu rst case declin post
thinprep uspstf chang interv guidelin pap test march
annual everi year implicit assumpt would
 thinprep revenu would elimin howev estim
cumul declin three-year period
busi stabil
second case look uspstf guidelin issu may
prostate-spec antigen screen prostat cancer
worst case would complet elimin test
quantic impact test manufactur look deriv
impact prostatectomi prostat cancer treatment volum report
intuit surgic radiat therapi servic centuri
oncolog hold given test typic rst line diagnost
men without symptom believ treatment volum highli
correl test gener cumul declin
treatment volum two-year report analogu case indic
potenti impact guidelin chang actual realiz
two/thre year period stabil thu impact anoth updat
uspstf cervic cancer screen guidelin would mitig compar
strict guidelin adher might impli
thought interest draft uspstf eventu last year
soften stanc screen prostat cancer year
much protest industri advoc uspstf state decis
prostat cancer screen individu one men
 year men discuss decis doctor
recommend analog might prove instruct investor
think futur cervic cancer screen recommend
molecular golden child growth like deceler
molecular diagnost busi sale jewel
diversi portfolio sizeabl busi unit outperform
expect inde molecular diagnost account nearli
half organ revenu growth
optimist remain best busi organ growth
rate well compani averag next sever year long product
cycl strong recur revenu stream lead competit posit
full menu viral load test hepat last remain
gap anticip fda approv help drive growth
abil expand exist market help custom drive
complianc test guidelin said see number reason
organ sale growth deceler meaning post
later inning panther instrument placement cycl
primari driver molecular diagnost growth panther
instrument placement util howev believ compani like
inning instrument placement alreadi track well
toward market opportun identi initi launch plan end
 placement compar loos identi
custom opportun identi launch plan gen-prob
analyst day compani identi lab target key european
market launch plan compar intern panther
placement comparison entir apples-to-appl
custom could one panther market opportun
could well larger compani envis back said
nonetheless infer launch later inning
gen-prob analyst day deutsch bank hundr placement opportun countri includ poland austria
believ increment panther-rel growth like increasingli come
higher level util see heavier lift futur menu addit
viral load largest opportun expect share gain
market next year model ramp viral load
sale beyond viral load see obviou compel
menu addit rather mani addit consid singl test
respiratori virus hospit acquir infect competit market
mani case best suit cartridge-bas dissemin test futur test
higher level multiplex addit remain seen
well market surviv higher level reimburs scrutini whether
market central away cartridge-bas system
open channel capabl lab develop test addit
focu workshop attend associ molecular
patholog annual meet last novemb howev dollar opportun
associ suppli reagent lab develop test tend
small addit capabl increasingli becom tabl stake roch
announc open channel capabl coba instrument late
last year see opportun support companion diagnost develop
eort open channel capabl market companion
diagnost tend small
competitor stand still expect major announc next
panther great instrument competitor look close
gap instrument menu think two biggest competit
item ag
roch menu expans coba instrument
higher throughput panther tests/
shift respect vs tests/shift panther expect roch
could receiv fda clearanc chlamydia/gonorhhea ct/ng test
strongest market coba instrument earli
moreov one largest diagnost custom labcorp lh
alreadi announc adopt coba back oct
intend expand menu instrument someth plagu
stock roch place coba
instrument sinc sept introduct healthi result track
initi adopt tigri instrument
 launch onclar hpv assay
assay current evalu fda expect approv
lack hpv test glare hole oer
back lost quest ct/ng busi back
abbott work new instrument platform
molecular though detail thin date plan launch
molecular instrument alin intern
contract bid
pressur medicar cut clinic lab fee schedul clf part
protect access medicar act pama could trickl lab supplier
like stand reason payment hospit refer lab
custom get squeez lab turn heighten eort nd save
supplier form price concess supplier typic
insul rapid chang custom behavior long-term contract
howev risk compani disclos
contract two key diagnost custom renew
next year infer one might quest sinc origin
strateg contract quest announc june year term thu
might forefront eort lab extract concess
supplier tight reimburs environ around time
competitor plug key menu gap molecular oer
meaning custom concentr busi
diagnost largest custom diagnost compris
gyn surgic busi miss street revenu forecast everi quarter
quarter row sinc benet ethicon dec withdraw
novasur competitor thermachoic annual
figur gyn surgic miss continu novasur declin steepen
compani report deutsch bank novasur result db estim
competit environ novasur intensi
studi issu behind novasur product endometri
ablat unveil
uncov interest competit product minerva surgic fda
approv sinc recent obtain label updat year
fda approv endometri ablat devic plan launch
appear respons heighten competit intens
feb launch nextgen novasur product novasur
advanc product incorpor design modic intend enhanc
patient comfort improv physician eas use howev benet
product yet born nancial
myosur strength less increment opportun
therapeut way
sinc initi fda clearanc built myosur product
devic uterin broid remov nearli franchis compani
continu add franchis launch myosur manual
product design better penetr in-oc market uterin tissu
remov myosur product big success see less room
market penetr probabl market opportun
thu believ growth could meaning slow report
year prior
moreov see emerg new therapeut treat pain associ
uterin broid perhap encroach myosur territori
margin rst esyma allergan target
fda approv two addit drug elagolix abbvie/neurocrin
relugolix myovant could receiv uterin broid indic thereaft
elogolix ph data expect soon fda approv perhap one physician
spoke anticip avail drug would reduc
surgic volum broid remov
period end expens share share sale growth ex acquir intang cash flowoper cash cash present conform adjust ep report compani exclud blood base onward consist compani presentationsourc deutsch bank compani file
period end asset cash receiv incom tax held expens defer tax current plant intang asset liabil current portion long term current current debt net incom tax long-term liabil stockhold januari
